Ari D. Baron, M.D., is Chief of the Division of Hematology Oncology at California Pacific Medical Center (CPMC), and Associate Clinical Professor of Medicine at UCSF. His practice has been at CPMC for over 20 years.
Dr. Baron is the Medical Director of Clinical Oncology Research at CPMC, and the Chair of the Science Committee for Sutter Health Cancer Research Group. He also serves on the Board of Governor’s for South West Oncology Group (SWOG), one of the largest National Cancer Institute cooperative cancer research groups.
Dr. Baron's main focus is in clinical research, where he has helped develop new medications for cancer patients across a broad array of diseases. He specializes in gastrointestinal cancers of the colon, liver, and pancreas, and urologic malignancies of the prostate and bladder.
Dr. Baron was one of the clinical oncology leads at Sutter Health enrolling patients to the TAPUR™ study, a national, prospective, non-randomized clinical trial determining the safety and efficacy of approved, targeted anticancer drugs.
He has co-authored numerous peer-reviewed publications in high-impact journals such as The New England Journal of Medicine, The Lancet, and the Journal of the American Medical Association.
These studies have helped secure FDA approval for treatments such as bevacizumab (Avastin®) a drug that inhibits blood vessels from supplying cancers and was approved for the treatment of colon cancer, and nivolumab (Opdivo®) an immunotherapy for bladder cancer.
Sutter Health Research Enterprise
2100 Webster Street Suite 225
San Francisco, CA, 94115